Any day, split halfway: Flexibility in scheduling high-dose cisplatin-A large retrospective review from a high-volume cancer center.

Abstract

High-dose (HD) cisplatin remains the standard of care with chemoradiation for locally advanced oropharyngeal cancer (OPC). Cooperative group trials mandate bolus-HD (100 mg/m2  × 1 day, every 3 weeks) cisplatin administration at the beginning of the week to optimize radiosensitization-a requirement which may be unnecessary. This analysis evaluates the impact of chemotherapy administration day of week (DOW) on outcomes. We also report our institutional experience with an alternate dosing schedule, split-HD (50 mg/m2  × 2 days, every 3 weeks). We retrospectively reviewed 435 definitive chemoradiation OPC patients from 10 December 2001 to 23 December 2014. Those receiving non-HD cisplatin regimens or induction chemotherapy were excluded. Data collected included DOW, dosing schedule (bolus-HD vs split-HD), smoking, total cumulative dose (TCD), stage, Karnofsky Performance Status, human papillomavirus status and creatinine (baseline, peak and posttreatment baseline). Local failure (LF), regional failure (RF), locoregional failure (LRF), distant metastasis (DM), any failure (AF, either LRF or DM) and overall survival (OS) were calculated from radiation therapy start. Median follow-up was 8.0 years (1.8 months-17.0 years). DOW, dosing schedule and TCD were not associated with any outcomes in univariable or multivariable regression models. There was no statistically significant difference in creatinine or association with TCD in split-HD vs bolus-HD. There was no statistically significant association between DOW and outcomes, suggesting that cisplatin could be administered any day. Split-HD had no observed differences in outcomes, renal toxicity or TCD compared to bolus-HD cisplatin. Our data suggest that there is some flexibility of when and how to give HD cisplatin compared to clinical trial mandates.

• Authors: Jung Julie Kang, Vatche Tchekmedyian, Nader Mohammed, Alisa Rybkin, Sarin Kitpanit, Ming Fan, Huili Wang, Stephanie M Lobaugh, Zhigang Zhang, Anna Lee, Linda Chen, Yao Yu, Kaveh Zakeri, Daphna Y Gelblum, Nadeem Riaz, Sean M McBride, C Jillian Tsai, Marc A Cohen, Jennifer R Cracchiolo, Luc G Morris, Bhuvanesh Singh, Snehal Patel, Ian Ganly, Jay O Boyle, Richard J Wong, Juliana Eng, Wanqing Iris Zhi, Kenneth Ng, Alan L Ho, Lara A Dunn, Loren Michel, James V Fetten, David G Pfister, Nancy Y Lee, Eric J Sherman
• Journal: International journal of cancer (Int J Cancer) Vol. 149 Issue 1 Pg. 139-148 (07 01 2021) ISSN: 1097-0215 [Electronic] United States
• PMID: 33586179 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 UICC.

Chemical References

• Antineoplastic Agents
• Cisplatin

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (therapeutic use)
• Chemoradiotherapy (mortality)
• Cisplatin (therapeutic use)
• Drug Administration Schedule
• Female
• Follow-Up Studies
• Hospitals, High-Volume (statistics & numerical data)
• Humans
• Male
• Middle Aged
• Neoplasms (pathology, therapy)
• Prognosis
• Retrospective Studies
• Survival Rate